Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease
复制标题
DOI：
10.1016/j.coph.2014.11.001
复制
发表时间：
2015-02-01
影响因子：
4
通讯作者：
Amalric, Marianne
中科院分区：
文献类型：
--
作者：
Amalric, Marianne
基底神经节中多巴胺和谷氨酸之间的相互作用调节运动和认知行为的关键方面。代谢型谷氨酸（mGlu）受体是帕金森病（PD）中谷氨酸能功能障碍的关键调节剂。临床前证据表明，I组mGlu受体拮抗作用和II组和III组mGlu受体活化通过调节基底神经节中的兴奋性和抑制性传递来改善PD的运动机能学并减少L-DOPA诱导的运动障碍。在PD中也观察到情感和认知缺陷。这些症状的治疗具有挑战性，并强调需要新的有效和耐受性良好的药物治疗。因此，本文将审查目前可用的知识，针对mGlu受体的治疗潜力，以恢复运动和非运动症状的PD。
The interplay between dopamine and glutamate in the basal ganglia regulate critical aspects of motor and cognitive behavior. Metabotropic glutamate (mGlu) receptors are key modulators of glutamatergic dysfunction in Parkinson's disease (PD). Preclinical evidence demonstrate that group I mGlu receptor antagonism and groups II and Ill mGlu receptor activation improve motor symptomatology of PD and decrease L-DOPA-induced dyskinesia by regulating excitatory and inhibitory transmission in the basal ganglia. Emotional and cognitive deficits are also observed in PD. Treatment of these symptoms is challenging and underscore the need for novel effective and well tolerated pharmacological treatments. This article will thus review the currently available knowledge regarding the therapeutic potential of targeting mGlu receptors to restore motor and nonmotor symptoms of PD.